Population
Patients with Type 2 diabetes
Design
Review
Authors
Loading...
Should not yet alter T2D management; leaves open whether PAI-1/TAFI inhibition reduces cardiovascular events.
Elevated PAI-1 and TAFI contribute to impaired fibrinolysis and atherothrombosis in Type 2 diabetes, highlighting them as potential therapeutic targets to reduce cardiovascular risk.
Yoshimasa Aso (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: